SCHEMBL7199659

SCHEMBL7199659

O=C(NO)C1(O)CNCCC1S(=O)(=O)N1CCC(c2cccc(Cl)c2)CC1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.39
ADAMTS5 Q9UNA0 2/20 0.38
NPSR1 Q6W5P4 1/20 0.38
ADAM17 P78536 2/20 0.37
MMP2 P08253 7/20 0.37
ADAM10 O14672 4/20 0.37
MMP9 P14780 3/20 0.37
MMP13 P45452 4/20 0.37
MMP1 P03956 1/20 0.37
NR3C1 P04150 1/20 0.36
NR3C2 P08235 1/20 0.36
ERBB2 P04626 1/20 0.34
MMP3 P08254 1/20 0.34
USP5 P45974 1/20 0.34
DRD2 P14416 1/20 0.33
DRD4 P21917 1/20 0.33
DRD3 P35462 1/20 0.33
GRM2 Q14416 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7200489 0.88 USP5 (0.44) ADAMTS5MMP2ADAM10MMP9MMP13
SCHEMBL7202601 0.88 MMP2 (0.49) ADAMTS5ADAM17MMP2ADAM10MMP9
SCHEMBL7205721 0.88 MMP13 (0.45) HSD11B1MMP2MMP9MMP13MMP1
SCHEMBL7201610 0.88 MMP2 (0.47) ADAM17MMP2ADAM10MMP9MMP13
SCHEMBL7204170 0.86 HTR2C (0.48) ADAM17MMP2ADAM10MMP9MMP13
SCHEMBL7206963 0.84 HTR2C (0.49) MMP13MMP1
SCHEMBL7205654 0.83 MMP13 (0.54) MMP2MMP9MMP13MMP1MMP3
SCHEMBL7204092 0.82 HDAC4 (0.40) HSD11B1MMP2ADAM10MMP13ERBB2
SCHEMBL7204290 0.82 MMP2 (0.46) ADAM17MMP2ADAM10MMP13MMP1
SCHEMBL7205659 0.82 TP53 (0.41) HSD11B1ADAM17MMP2ADAM10MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6608104-B2 Antiarthritic agents; anticancer agents PFIZER INC 2003-08-19 US disclosed
US-20020019534-A1 Gem substituted hydroxamic acids PFIZER INC. 2002-02-14 US disclosed
EP-1138680-A1 Gem substituted sulfonyl hydroxamic acids as MMP inhibitors Pfizer Products Inc. (US) 2001-10-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019534-A1 Gem substituted hydroxamic acids MMP14, TOP2A, ADAMTS1 HSD11B1 1493/4885ADAMTS5 11/4885NPSR1 3387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.